Immune parameters affecting adenoviral vector gene therapy in the brain

Journal of NeuroVirology

Volumn 4, Issue 2, 1998, Pages 194-203

  Parr, Michael J ^a   Wen, Patrick Y ^b   Schaub, Meike ^b   Khoury, Samia J ^b   Sayegh, Mohamed H ^b   Fine, Howard A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adenovirus; Brain; Gene therapy; Inflammation; Neuroimmunology; galactosidase

Indexed keywords

BETA GALACTOSIDASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENE; VIRUS IMMUNITY;

EID: 0031961062     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550289809114519     Document Type: Article

References (39)

1. Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Peschanski MR (1993). Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genetics 3: 224-228.
2. Armentano D, Sookdeo CC, Hehir KM, Gregory RJ, St George JA, Prince GA, Wadworth SC, Smith AE (1995). Charaterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 6: 1343-1353.
3. Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A (1993). Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nature Genetics 3: 229-234.
4. Bett AJ, Haddara W, Prevec L, Graham FL (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 91: 8802-8806.
5. Byrnes AP, Rusby JE, Wood MJA, Charlton HM (1995). Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66: 1015-1024.
6. Byrnes AP, Wood MJA, Charlton HM (1996). Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Therapy 3: 644-651.
7. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ (1993). A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genetics 3: 219-223.
8. DeMatteo RP, Raper SE, Ahn M, Fisher KJ, Burke C, Radu A, Widera G, Claytor BR, Barker CF, Markmann JF (1995). Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus. Annals Surgery 222: 229-242.
9. Dong Y, Wen PY, Manome Y, Parr MJ, Hirschowitz A, Chen L, Hirschowitz E, Crystal RG, Kufe DW, Fine HA (1996). In vivo replication-deficient adenovirus vector mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 7: 713-720.
10. Engelhardt JF, Ye X, Doranz B, Wilson JM (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91: 6196-6200.
11. Fabry Z, Raine CS, Hart MS (1994). Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 5: 566-571.
12. Graham FL, Smilely J, Russel WC, Nairn R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-72.
13. Guerette B, Vilquin JT, Gingras M, Gravel C, Wook KJ, Tremblay JP (1996). Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLAIg. Hum Gene Ther 7: 1455-1463.
14. Haecker SE, Stedman HH, Balice-Gordon RJ, Smith DB, Greelish JP, Mitchell MA, Wells A, Sweeney HL, Wilson JM (1996). In vivo expression of full length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 7: 1907-1914.
15. Hirschowitz E, Ohwada A, Pascal WR, Russi TJ, Crystal RG (1995). In vivo adenovirus-mediated gene transfer of the E. coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 6: 1055-1063.
16. Kajiwara K, Byrnes AP, Charleton HM, Wood MJA, Wood KJ (1997). Immune responses to adenoviral vectors during gene transfer in the brain. Hum Gene Ther 8: 253-265.
17. Kay MA, Holterman AX, Meuse L, Gown A, Ochs HD, Linsley PS, Wilson CB (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genetics 11: 191-197.
18. Kay MA, Meuse L, Gown AM, Linsley P, Hollenbaugh D, Aruffo A, Ochs HD, Wilson CB (1997). Transient immunosuppression with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 94: 4686-4691.
19. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW (1995). CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunology 155: 4521-4524.
20. Kobayashi N, Allen N, Clendenon NR, Ko LW (1980). An improved rat brain-tumor model. J Neurosurg 53: 808-815.
21. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT (1996). A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 93: 5731-5736.
22. Kozarsky KF and Wilson JM (1993). Gene therapy: adenovims vectors. Curr Op Genetics Devel 3: 499-503.
23. Krougliak V, Graham FL (1995). Development of cell lines capable of complementing E1, E4 and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 6: 1575-1586.
24. Lee MG, Abina MA, Haddada H, Perricaudet M (1995). The constitutive expression of the immunomodulatory gp19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 2: 256-262.
25. Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG, Magovern CJ, Isom OW, Rosengart T, Falk-Pedersen E, Hackett NR, Crystal RG, Mastrangeli A (1997). Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Therapy 8: 99-109.
26. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cremediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93: 13565-13570.
27. Parks RJ, Wilson JM (1997). A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virology 71: 3293-3298.
28. Stratford-Perricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P (1990). Evaluation of the transfer and expression in mice of an enzyme encoding gene using a human adenovirus vector. Hum Gene Ther 1: 241-256.
29. Tripathy SK, Black HB, Goldwasser E, Leiden JM (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Medidne 2: 545-550.
30. Wilson C, Kay MA (1995). Immunomodulation to enhance gene therapy. Nature Medicine 1: 887-889.
31. Wold WSM, Gooding LR (1991). Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 184: 1-8.
32. Wood MJA, Charlton HM, Wood KJ, Kajiwara K, Byrnes AP (1996). Immune responses to adenovirus vectors in the nervous system. Trends Neuroscience 19: 497-501.
33. Worgall S, Wolff G, Falck-Pedersen E, Crystal R (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8: 37-44.
34. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM (1994a). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407-4411.
35. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM (1994b). Inactivation of E2a in recombinant adenovirus improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 7: 363-369.
36. Yang Y, Li Q, Ertl HCJ, Wilson JM (1995a). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virology 69: 2004-2015.
37. Yang Y, Xiang Z, Ertl HCJ, Wilson JM (1995b). Upregulation of class 1 major histocompatibility complex antigens by interferon-γ is necessary for T-cell mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 92: 7257-7261.
38. Yang Y, Trinchieri G, Wilson JM (1995c). Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Medicine 1: 890-893.
39. Yang Y, Wilson JM (1995). Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunology 155: 2564-2570.